Register Login

SILENCE THERAPEUTICS PLC (SLN)

(10% Negative) SILENCE THERAPEUTICS PLC (SLN) Announces Delay in upon Trials for connection wit Due to Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot June 23, 2026, 8:40 p.m.

    📋 SILENCE THERAPEUTICS PLC (SLN) - Clinical Trial Update

    Filing Date: 2026-06-23

    Accepted: 2026-06-23 16:35:22

    Event Type: Clinical Trial Update

    Event Details:

    SILENCE THERAPEUTICS PLC (SLN) Announces Clinical Trial Update SILENCE THERAPEUTICS PLC (SLN) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: upon, arising
    • Diseases/Conditions: connection wit, certain jurisdictions may be restricted by law
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Regulatory Process
      • anticipated in 2026
      • planned for the treatment of HoFH which is the area of highest unmet need where >90% of patients don’t reach the LDL-C goal despite being treated with multiple lipid lowering therapies 1. Heterozygous familial hypercholesterolemia: prevalence and control rates I 2021
      • Expected in 3Q 2026

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: SILENCE THERAPEUTICS PLC
    • Ticker Symbol: SLN

Search

News categories